HCRTR1 and migraine disorder: The new targets for migraine therapy, such as CGRP receptor antagonist or anti-CGRP antibody, 5-HT1F agonist, glutamate antagonist and dual hypocretin-1 receptor antagonist, are currently in phase II clinical trials [95, 96].